E
Editas Medicine
Unlocking the promise of genome editing to deliver life-changing medicines
At a glance
- Status
- Listed
- Listing
- IPO 2016
News
Knowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Market map
1k+ Global Genetics & Genomics startups
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in United States
Open roles
Editas Medicine in the Cambridge ecosystem
The Editas Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Juno Therapeutics
Flagship Pioneering
Polaris Partners
Third Rock Ventures- PFPartners Innovation Fund
Series B and later12 investors entered at this stage
- ECEcoR1 Capital
Casdin Capital- VIViking Global Investors
- OFOmega Funds
T. Rowe Price- HUHarvard University
- AIAlexandria Venture Investments
Khosla Ventures- JAJennison Associates
Fidelity Investments- DEDeerfield
- BNBoris Nikolic
Source: Dealroom Talent Intelligence.
Alumni founders
Former Editas Medicine employees who went on to found companies, sorted by Dealroom signal score.
KTKate TherapeuticsEst. 2020
Sharif TabebordbarUnited States
BTBeam TherapeuticsEst. 2017
PAPairwiseEst. 2017
David LiuUnited States
GBGate BioscienceEst. 2021
MBMammoth BiosciencesEst. 2017
Jennifer A. DoudnaUnited StatesPatents
71 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Editas Medicine on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.